Sanofi CEO warns of short-term vaccine demand weakness in US due to misinformation and administration scrutiny.
ByAinvest
Wednesday, Jan 14, 2026 2:27 pm ET1min read
SNY--
Sanofi's CEO, Paul Hudson, expects a slight weakness in US vaccine demand this year due to misinformation and heightened scrutiny under the current administration. The company reported a decline in vaccine sales in Q3 and expects demand to stabilize over time. Hudson believes that policy uncertainty has created favorable conditions for vaccine-focused M&A. Combined flu-COVID vaccines could drive the next wave of vaccine uptake from 2027 or 2028, particularly among older adults.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet